Zhejiang Pharmaceutical (600216): Vitamins bottomed out, Q1 performance recovered significantly, and emphasis was placed on R&D and the pharmaceutical business progressed in an orderly manner

Incident 1: The company released its 2023 annual report. In 23, the company achieved operating income of 7.8 billion yuan, -4% year-on-year, and net profit to mother of 430 million yuan, -20% year-on-year; of these, Q4 achieved revenue of 19 million yuan in a single quarter

光大證券Apr 30 11:56

Express News | Zhejiang Pharmaceutical: The subsidiary received a notice of approval for the marketing application of engagliptin chemical raw materials

BreakingsApr 29 15:45

Zhejiang Pharmaceutical (600216): Vitamin prices are picking up, business conditions are improving in 1Q24

The 2023 results were lower than our expectations. 1Q24 was in line with our expectations Zhejiang Pharmaceutical's 2023 revenue of 7.794 billion yuan, -4.0% year over year; net profit to mother was 465 million yuan, corresponding to profit of 0.48 yuan per share

中金公司Apr 26 10:41

Express News | Zhejiang Pharmaceutical: Achieved revenue of 2,249 billion yuan in the first quarter, up 12.01% year on year; net profit of 110 million yuan, down 3.44% year on year.

BreakingsApr 25 17:52

Zhejiang Pharmaceutical (600216.SH): Net profit of 110 million yuan in the first quarter decreased by 3.44% year on year

On April 25, Ge Longhui (600216.SH) released its first quarter report. Operating revenue was 2,249 million yuan, up 12.01% year on year, net profit of 110 million yuan, down 3.44% year on year, after deducting non-net profit of 106 million yuan, up 8.07% year on year, with basic earnings per share of 0.11 yuan.

Gelonghui FinanceApr 25 17:36

Zhejiang Pharmaceutical (600216.SH): Currently, the company's NMN products are only exported and sold to some overseas countries or regions that allow the product to be sold as a health product

Gelonghui, March 29丨Zhejiang Pharmaceutical (600216.SH) said on the investor interactive platform that NMN products cannot be registered and sold as pharmaceuticals or health products under current domestic regulations. Currently, the company's NMN products are only exported and sold to some overseas countries or regions that allow the product to be sold as health products. This business is an export/cross-border business being cultivated by the company's health products sector, and sales volume in 2023 will not be significant.

Gelonghui FinanceMar 29 18:40